News about Drug Discovery & Development

Nxera Pharma to Get USD 35 Million from Neurocrine for Phase 2 Trial with NBI- '568

The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI- ‘568 into Phase 3 clinical trials in early 2025.

Drug Discovery & Development | 03/09/2024 | By Aishwarya |  406

Novavax 2024-2025 Formula COVID-19 Vaccine Gets EUA for Use in US

Pre-filled syringes of the vaccine will be available in thousands of locations, including retail and independent pharmacies and regional grocers, following the Center for Biologics Evaluation and Research release of vaccine batches.
<br />

Drug Discovery & Development | 02/09/2024 | By Aishwarya |  932

Natco Pharma Submits ANDA for Generic Version of TABRECTA

Natco claims to be the first company to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of the potential launch of the product under certain circumstances.

Drug Discovery & Development | 31/08/2024 | By Aishwarya |  952

Zydus Gets Final Approval from USFDA for Scopolamine Transdermal System

Scopolamine Transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery.

Drug Discovery & Development | 31/08/2024 | By Aishwarya |  637

Biocon Biologics Signs License Deal with Janssen for Bmab 1200

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan. Regulatory filings in these markets are currently under review.

Drug Discovery & Development | 29/08/2024 | By Aishwarya |  519

Alembic Gets FDA Approval for Betamethasone Valerate Foam

Betamethasone valerate foam, 0.12 percent, is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

Drug Discovery & Development | 27/08/2024 | By Aishwarya |  507

BioIVT Acquires ZenBio to Expand its Pharmaceutical Portfolio

Together, BioIVT and ZenBio will offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, as well as blood products for pharmaceutical and cosmetics companies.

Drug Discovery & Development | 26/08/2024 | By Aishwarya |  446

Sun Pharma Launches a Tedizolid Phosphate Tablets in India

STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Drug Discovery & Development | 26/08/2024 | By Aishwarya |  1035

RedHill Biopharma Announces Roll Out of Talicia in UAE

The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  1187

Bridge Biotherapeutics and HitGen to Advance Novel Cancer Therapeutics Program

Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  593